Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Youyou Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5582-2373; OpenAlex author ID A5062753310. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. AZD5153 enhances the chemo-sensitivity of gemcitabine on pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1186/s12935-025-03952-2↗
  2. Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway. First author DOI 10.1111/jcmm.17109↗
  3. A novel derivative of valepotriate inhibits the PI3K/AKT pathway and causes Noxa-dependent apoptosis in human pancreatic cancer cells. Co-author DOI 10.1038/s41401-019-0354-1↗
  4. Active ingredients of Inula helenium L. exhibits similar anti-cancer effects as isoalantolactone in pancreatic cancer cells. Co-author DOI 10.1080/14786419.2018.1543676↗
  5. The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR. Co-author DOI 10.1186/s12935-020-01548-6↗
  6. Ethyl acetate extract from Inula helenium L. inhibits the proliferation of pancreatic cancer cells by regulating the STAT3/AKT pathway. Co-author DOI 10.3892/mmr.2018.8534↗
  7. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice. First author DOI 10.1016/j.intimp.2015.04.014↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nengming Lin · 4 shared papers, 2018–2025 · strength 0.59
  2. Biqin Tan · 2 shared papers, 2020–2025 · strength 0.36
  3. Rong Dong · 2 shared papers, 2020–2025 · strength 0.36
  4. Nengming Lin · 2 shared papers, 2020–2022 · strength 0.27
  5. Bo Zhang · 2 shared papers, 2020 · strength 0.24
  6. Lulin Zhu · 1 shared paper, 2025 · strength 0.23
  7. Bo Zhang · 1 shared paper, 2025 · strength 0.23
  8. Bo Zhang · 1 shared paper, 2022 · strength 0.15
  9. Fei Wang · 1 shared paper, 2020 · strength 0.13
  10. Jing Chen · 1 shared paper, 2020 · strength 0.12
  11. Bo Zhang · 1 shared paper, 2018 · strength 0.09
  12. Xuan Wei · 1 shared paper, 2015 · strength 0.05
  13. Chao Lin · 1 shared paper, 2015 · strength 0.05
  14. Xuewen Zhang · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.